Revium Rx. (RVRC) Form 10-Q — May 14, 2026
Revium Rx reported a net loss of $725,000 for the first quarter of 2026, driven by $473,000 in R&D expenses and $266,000 in G&A costs, leaving the company with approximately $2.1 million in cash and short-term deposits. The filing includes a critical going-concern warning, stating that substantial doubt exists about the company’s ability to continue as a going concern due to its accumulated deficit of $25.7 million and lack of binding commitments for further investment.
Key figures
- Shares Outstanding
- 60729100
- Ga expenses q1
- 266
- Rd expenses q1
- 473
- Operating loss q1
- 739
- Accumulated deficit
- 25687
- Options outstanding
- 3530000
Price after filing
Close on the filing date to close N calendar days later (from $1.67). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.